AIP
GILD icon

ARS Investment Partners’s Gilead Sciences GILD Stock Holding History

ARS Investment Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,400
Closed -$332K – 130
2018
Q1 		$332K Sell
4,400
-1,200
-21% -$95.4K 0.04% 134
2017
Q4 		$401K Sell
5,600
-10
-0.2% -$759 0.05% 136
2017
Q3 		$455K Hold
5,610
– – 0.06% 133
2017
Q2 		$397K Hold
5,610
– – 0.05% 134
2017
Q1 		$381K Buy
5,610
+50
+0.9% +$3.52K 0.06% 132
2016
Q4 		$398K Buy
+5,560
New +$413K 0.06% 138

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ARS Investment Partners's GILD Position: Q2 2018 in Review

ARS Investment Partners sold out of Gilead Sciences (GILD) in Q2 2018, closing a stake of 4,400 shares — an estimated $332K sold.

ARS Investment Partners first reported a position in GILD in Q4 2016 and held it in 6 quarters. The position peaked at $455K in Q3 2017. 1,522 funds tracked by Wall St. Rank hold GILD as of Q2 2018.

  • ARS Investment Partners reported no remaining Gilead Sciences position as of Q2 2018 after selling out during the quarter.
  • ARS Investment Partners sold 4,400 Gilead Sciences shares in Q2 2018, an estimated $332K.
  • ARS Investment Partners first reported a position in Gilead Sciences in Q4 2016 and held it in 6 quarters.
  • ARS Investment Partners's Gilead Sciences position peaked at $455K in Q3 2017.
  • 1,522 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2018.

Based on ARS Investment Partners's 13F filing for Q2 2018, filed 13 Aug 2018.